Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$5.00 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$20.62M
Enterprise Value$308.70M
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding1,779,275
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap14.97
Enterprise Value/Revenue23.96
Enterprise Value/Gross Profit24.02
Enterprise Value/Ebitda-50.25
Forecast
1Y Price Target
$47.50Price Target Upside195.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.23
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Non-dilutive Partnership FundingMaterial upfront and milestone payments from established partners provide durable, non-dilutive capital, validating Palatin’s science and extending runway without immediate equity issuance. This funding model reduces near-term dilution risk and supports ongoing IND-enabling and clinical work.
Peptide MC4R Program Advancing To INDProgressing a lead clinical asset toward regulatory submission is a durable value driver: an IND filing enables clinical trials and potential partnering/royalty paths. Demonstrable program milestones de-risk development stages and can unlock additional non-dilutive or licensing opportunities.
Platform Leverage And Sublicensing StrategyA strategy focused on sublicensing and partnerships diversifies commercialization pathways and spreads development risk. Multiple programs and new IP increase optionality for deals, milestone income and royalties, making long-term cash generation less binary than single-product models.
Bears Say
Limited Cash RunwayA runway only to mid-2027 creates structural funding risk: management must secure additional capital or milestone receipts to sustain development. This constraint pressures program timing, partnership negotiations and could force dilutive financings if non-dilutive inflows don't materialize on schedule.
Persistent Cash Burn And Negative FCFSustained negative operating and free cash flow signals structural inability to self-fund growth. Continued cash burn necessitates recurrent external funding, which can dilute shareholders and constrain strategic flexibility, especially if revenues remain small and volatile versus ongoing R&D spend.
Competitive & Clinical Risk / Timing SetbacksBeing years behind an approved competitor and facing unresolved safety translational risks reduces commercial upside and increases development risk. Delays and deprioritizations (eg, earlier oral candidate) extend time-to-market, amplify competitive disadvantage, and can hinder partner interest and pricing power.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $5.00 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $20.62M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 135 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all PTN earnings summariesPTN Stock 12 Month Forecast
Average Price Target
$47.50
▲(195.95% Upside)
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
11.15% Insiders
1.96% Mutual Funds
27.39% Other Institutional Investors
58.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---